Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

125.93
+1.230.99%
Post-market: 125.930.00000.00%19:30 EDT
Volume:12.66K
Turnover:1.59M
Market Cap:550.31M
PE:6.53
High:126.04
Open:125.39
Low:125.29
Close:124.70
52wk High:131.68
52wk Low:90.01
Shares:4.37M
Float Shares:4.37M
Volume Ratio:0.61
T/O Rate:0.29%
Dividend:1.06
Dividend Rate:0.84%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.65
PE(LYR):5.79

Loading ...

FDA Approves Shorter Monitoring Time for Amgen’s Imdelltra First Two Doses

Reuters
·
Sep 14

Amgen - Imdelltra Monitoring Reduced to 6-8 Hours for First Two Infusions

THOMSON REUTERS
·
Sep 14

Amgen - Imdelltra Monitoring Remains 6-8 Hours for Third Dose, 3-4 Hours for Cycles 3-4

THOMSON REUTERS
·
Sep 14

FDA Approves Reduced Monitoring Time for First Two Doses of Imdelltra®

THOMSON REUTERS
·
Sep 14

Amgen - Patients to Receive Follow-up Assessment After First Two Imdelltra Doses

THOMSON REUTERS
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Johnson & Johnson reports PAPILLON study meets primary endpoint

TIPRANKS
·
Sep 14

Market Chatter: Apollo Global in Talks to Buy J&J Orthopedics Unit for $20 Billion

MT Newswires Live
·
Sep 14

One State's Battle to Stop People from Taking Unapproved Weight-Loss Drugs

Dow Jones
·
Sep 14

Nanobiotix announces updated safety, efficacy data from JNJ-1900 study

TIPRANKS
·
Sep 14

Sino Biopharmaceutical Stock Advances 4.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 14

Johnson & Johnson Says Lung Cancer Drug Combination Extends Median Survival to Over 34 Months

MT Newswires Live
·
Sep 14

J&J Shares up 1.2% Premarket After Report Co's Orthopedics Unit Draws Apollo Interest in Potential $20 Bln Deal

THOMSON REUTERS
·
Sep 14

Dow Jones Top Company Headlines at 1 am ET: Biggest AI Rivals Agree They Need to Slow it Down | Amazon ...

Dow Jones
·
Sep 14

J&J - Rybrevant Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Nsclc

THOMSON REUTERS
·
Sep 14

Dow Jones Top Company Headlines at 9 PM ET: Amazon Pauses Operations with 21 Air After Miami Crash | Pfizer ...

Dow Jones
·
Sep 14